Forest Laboratories, Inc. & Nycomed Announce a Conference Call to Review Publication of Daxas® Phase III Clinical Trial Results
August 27 2009 - 6:45PM
Business Wire
Forest Laboratories, Inc. (NYSE: FRX), an international
manufacturer and marketer of pharmaceutical products and Nycomed, a
privately owned pharmaceutical company, will host a conference call
at 7:15 AM EDT on Friday, August 28, 2009. Dr. Lawrence Olanoff,
President and Chief Operating Officer of Forest Labs, Dr. Marco
Taglietti, President of Forest Research Institute, Dr. Anders
Ullman, Executive Vice President R&D of Nycomed and Professor
Fernando Martinez from the University of Michigan will discuss the
results of the Daxas® Phase III clinical trials that were published
in The Lancet today.
The conference call will be webcast live beginning at 7:15 AM
EDT on the Company's website www.frx.com and also on the website
www.streetevents.com. Please log on to either website at least
fifteen minutes prior to the conference call as it may be necessary
to download software to access the call. A replay of the conference
call will be available until September 11, 2009 at both websites
and also by dialing 1-800-642-1687 (US investors) or
+1-706-645-9291 (international investors), Conference Call ID
27580393.
About Nycomed
Nycomed is a privately owned global pharmaceutical company with
a differentiated portfolio focused on branded medicines in
gastroenterology, respiratory and inflammatory diseases, pain,
osteoporosis and tissue management. An extensive range of OTC
products completes the portfolio. Its R&D is structured around
partnerships and in-licensing is a cornerstone of the company's
growth strategy.
Nycomed employs 12,000 associates worldwide, and its products
are available in more than 100 countries. It has strong platforms
in Europe and in fast-growing markets such as Russia/CIS and Latin
America. While the US and Japan are commercialized through
best-in-class partners, Nycomed plans to further strengthen its own
position in key Asian markets.
Headquartered in Zurich, Switzerland, the company generated
total sales of €3.4 billion in 2008 and an adjusted EBITDA of
€1.2 billion. For more information visit www.nycomed.com.
Media:
General phone: +41 44 555 15 10 Beatrix Benz, phone: +41 79 218
9824 Tobias Cottmann, phone: +41 44 555 15 01
Investors:
Christian B. Seidelin, phone: +41 44 555 11 04
About Forest
Laboratories
Forest Laboratories (NYSE: FRX) is a U.S.-based pharmaceutical
company with a long track record of building partnerships and
developing and marketing products that make a positive difference
in people’s lives. In addition to its well-established franchises
in therapeutic areas of the central nervous and cardiovascular
systems, Forest’s current pipeline includes product candidates in
all stages of development and across a wide range of therapeutic
areas. The company is headquartered in New York, NY. To learn more
about Forest Laboratories, visit www.frx.com.
Except for the historical information contained herein, this
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These
statements involve a number of risks and uncertainties, including
the difficulty of predicting FDA approvals, the acceptance and
demand for new pharmaceutical products, the impact of competitive
products and pricing, the timely development and launch of new
products, and the risk factors listed from time to time in Forest
Laboratories’ Annual Report on Form 10-K, Quarterly Report on Form
10-Q, and any subsequent SEC filings.
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jul 2023 to Jul 2024